SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern
A novel variant of concern (VOC) named CAL. 20C (B. 1.427/B. 1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …
[HTML][HTML] Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …
variants were first identified in the United Kingdom and South Africa, respectively, and have …
[HTML][HTML] The germinal centre B cell response to SARS-CoV-2
BJ Laidlaw, AH Ellebedy - Nature Reviews Immunology, 2022 - nature.com
The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …
cells and memory B cells capable of mediating long-term protective immunity …
[HTML][HTML] Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants
Neutralizing Activity against SARS-CoV-2 Variants Among samples obtained from persons
who had received the mRNA-1273 or BNT162b2 vaccines, neutralizing antibody titers …
who had received the mRNA-1273 or BNT162b2 vaccines, neutralizing antibody titers …
[HTML][HTML] Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples …
variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples …
Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study
Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …
[HTML][HTML] Tackling COVID-19 with neutralizing monoclonal antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …
[HTML][HTML] Escape of SARS-CoV-2 501Y. V2 from neutralization by convalescent plasma
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations,
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS …
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
L Stamatatos, J Czartoski, YH Wan, LJ Homad, V Rubin… - Science, 2021 - science.org
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
[HTML][HTML] Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
J Hu, P Peng, X Cao, K Wu, J Chen, K Wang… - Cellular & Molecular …, 2022 - nature.com
On 24 November, a new detected variant B. 1.1. 529 of SARS-CoV-2 by South Africa was
reported to WHO. After only 2 days, this variant was designated as “variant of concern”(VOC) …
reported to WHO. After only 2 days, this variant was designated as “variant of concern”(VOC) …